CytomX CFO awarded options and milestone PSUs totaling 117,400 (CTMX)
Rhea-AI Filing Summary
CytomX Therapeutics (CTMX) Chief Financial Officer Christopher Ogden reported option and performance‑unit awards on Sept 26, 2025. He was granted a stock option to buy 78,250 shares at a $2.90 exercise price that vests monthly over four years beginning Sept 26, 2025, and 39,150 Performance Stock Units (PSUs) that vest in three tranches tied to clinical milestones, each PSU convertible into one share on vesting. Following these awards, Mr. Ogden beneficially owns 78,250 option shares and 39,150 PSUs, all held directly. The option expires Sept 25, 2035. The filing is signed Sept 30, 2025.
Positive
- Alignment of incentives: Option vests monthly over four years, supporting retention.
- Performance linkage: 39,150 PSUs vest upon clinical milestones, tying compensation to development outcomes.
- Transparent disclosure: Filing provides vesting schedules, exercise price ($2.90), expiry (09/25/2035), and quantities.
Negative
- Potential future dilution: Total of 117,400 equity interests could dilute existing shareholders if exercised or settled.
- Concentration in executive compensation: Large grant to a single officer may be material depending on company size (company size not provided in this filing).
Insights
TL;DR: Insider received standard grant-based compensation: an option and milestone-driven PSUs totaling 117,400 equity interests.
The grants indicate compensation tied to service and clinical progress rather than immediate stock transfers. The option vests monthly over four years, aligning retention incentives, while PSUs vest upon achievement of three clinical milestones, aligning pay with development objectives. The exercise price of $2.90 and ten-year term are typical for executive option awards. The direct ownership of these instruments means potential future dilution if and when exercised or settled.
TL;DR: Grants reflect governance-standard practices linking pay to tenure and milestone achievements.
The structure—time‑based option vesting and milestone‑based PSUs—follows common governance practices to align executive incentives with long‑term company performance and clinical progress. The clear vesting schedules and direct ownership are disclosed appropriately. The filing contains required detail on vesting commencement, milestone structure, and security terms, enabling investors to assess potential dilution timing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 78,250 | $0.00 | -- |
| Grant/Award | Performance Stock Units (PSUs) | 39,150 | $0.00 | -- |
Footnotes (1)
- 1/48th of the shares subject to the option vest on each monthly anniversary measured from September 26, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date. Each Performance Stock Unit ("PSU") represents a contingent right to receive one (1) share of Common Stock upon vesting. 1/3 of the PSUs vest upon the achievement of each of three clinical milestones, subject to the Reporting Person continuing as a service provider through each such date.
